HopeStage
Back to overview

Schizophrenia studies

Topics
More filters

Some studies do not list a clear city. Always confirm the location with the study team.

Some visits may still be in person. Participation depends on the study’s location and eligibility requirements.

Schizophrenia

Schizophrenia can affect how a person perceives reality, thinks and feels, sometimes involving hearing voices or holding unusual beliefs.

4505studies shown
Showing 589-600 of 4,505
Drug study icon
CompletedNCT01786239

Omega-3 Dietary Supplements in Schizophrenia

Official study title

Detecting Which Patients With Schizophrenia Will Improve With Omega-3 Treatment

This study has finished and is no longer accepting participants.

In Glen Oaks
Schizophrenia, BipolarityMedication studyAges 15–40
Countries
United States
Sponsor
Delbert Robinson
Drug study icon
CompletedNCT01602029

Double Blind Placebo Control Study in people with Schizophrenia

Official study title

Randomized Double Blind Placebo Controlled Study of Ondansetron and Simvastatis Added to Treatment As Usual in Patients with Schizophrenia

This study has finished and is no longer accepting participants.

Multiple locations, including Karachi
SchizophreniaMedication studyAges 18–65
Countries
Pakistan
Sponsor
Pakistan Institute of Living and Learning
Drug study icon
TerminatedACTRN12610000244000

Quetiapine medication and psychological therapy for Schizophrenia

Official study title

The NEURAPRO-Q (North America, EURope, Australia PROdrome) Study: A multicentre randomised controlled trial (RCT) to evaluate the effect of Quetiapine and Cognitive-Behavioural Case Management on the incidence of first episode psychosis in Symptomatic Patients at Ultra-High Risk for Early Progression to Schizophrenia and Other Psychotic Disorders

This study ended early.

In China
SchizophreniaInterventional studyAges 15–40
Countries
United States, China
Sponsor
Orygen Youth Health Research Centre
Drug study icon
CompletedACTRN12608000461392

study of a Selective Estrogen Receptor Modulator (raloxifene) in Schizophrenia

Official study title

Clinical Trial of a Selective Estrogen Receptor Modulator (raloxifene) in the treatment of cognitive deficits and psychotic symptoms of patients with schizophrenia

This study has finished and is no longer accepting participants.

In Randwick
SchizophreniaInterventional studyAges 18–55
Countries
Australia
Sponsor
University of New South Wales
Behavioral study icon
CompletedACTRN12621001081808

Reward learning and Cognitive Remediation

Official study title

The effect of cognitive remediation on reward learning in adults with schizophrenia spectrum disorder

This study has finished and is no longer accepting participants.

In Woolloongabba
SchizophreniaInterventional studyAges 18–35
Countries
Australia
Sponsor
Princess Alexandra Hospital and health service
Drug study icon
WithdrawnNCT05956600

An Single-Arm study Evaluating the Safety and Efficacy of Amisulpride in Treating people with Schizophrenia and Schizoaffective Disorder Who Have Treatment-Resistant Positive Symptoms

Official study title

An Open-Label, Single-Arm Clinical Trial Evaluating the Safety and Efficacy of Amisulpride in Treating Patients With Schizophrenia and Schizoaffective Disorder Who Have Treatment-Resistant Positive Symptoms

This study was withdrawn before enrollment.

Location not clearly listed
SchizophreniaMedication studyAges 18–65
Countries
Sponsor
University of California, Los Angeles
Behavioral study icon
CompletedNCT04298450

ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention

Official study title

ED to EPI: Using SMS (Text) Messaging to Improve the Transition From the Emergency Department to Early Psychosis Intervention for Young People With Psychosis

This study has finished and is no longer accepting participants.

In Toronto
Schizophrenia, Bipolarity, ...Behavioural studyAges 16–29
Countries
Canada
Sponsor
Centre for Addiction and Mental Health (Hospital / academic medical center)

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.